- Home
- FCBC vs RAPT Comparison
FCBC vs RAPT Comparison
Compare FCBC & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCBC | RAPT |
|---|---|---|
| Founded | 1874 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 612.1M | 498.4M |
| IPO Year | 1992 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FCBC | RAPT |
|---|---|---|
| Price | $40.79 | $57.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $56.22 |
| AVG Volume (30 Days) | 61.0K | ★ 4.1M |
| Earning Date | 01-27-2026 | 03-05-2026 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $167,428,000.00 | N/A |
| Revenue This Year | $10.69 | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | $15.59 | ★ N/A |
| Revenue Growth | ★ 3.18 | N/A |
| 52 Week Low | $31.21 | $5.67 |
| 52 Week High | $45.57 | $57.86 |
Technical Indicators
Market Signals| Indicator | FCBC | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 74.71 | 79.64 |
| Support Level | $33.00 | $57.61 |
| Resistance Level | $35.15 | $57.80 |
| Average True Range (ATR) | 1.34 | 0.12 |
| MACD | 0.72 | -0.22 |
| Stochastic Oscillator | 87.99 | 75.00 |
Price Performance
Historical ComparisonAbout FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.